Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Presentation TVT 2023

Late-Breaking Clinical Science: Three-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

Presenter: Firas Zahr

June 08, 2023

Presentation TVT 2022

Key features for a first valve in a low-risk patient

Presenter: Katherine Harrington

June 09, 2022

Presentation TVT 2021

TAVR and SAVR “Sequencing”: Lifelong Management Journey of Severe AS

Presenter: Isaac George

July 20, 2021

Presentation TVT 2021

Choosing the First TAVR Prosthesis: Self Expanding vs Balloon Expandable – Advantages and Disadvantages

Presenter: Uri Landes

July 20, 2021

Presentation TVT 2021

Clinical and Anatomic Considerations for TAVR in a Young Patient (<65 yo): Durability, Coronary Access, and More

Presenter: Gilbert Tang

July 20, 2021

Presentation TVT 2021

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

Presenter: John Forrest

July 20, 2021

Presentation TVT 2020

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Presenter: Bruce Rutkin

June 20, 2020

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

Reactions From the Surgical Community

Presenter: Patrick McCarthy

June 13, 2019

Presentation TVT 2019

Reactions From the Cardiology Community

Presenter: Blase Carabello

June 13, 2019

Presentation TVT 2019

Highlights From the CoreValve Low-Risk Trial

Presenter: Jeffrey Popma

June 13, 2019

Presentation TVT 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presenter: Michael Mack

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

Presentation TVT 2019

The Evolut Low-Risk Randomized Trial

Presenter: Steven Yakubov

June 13, 2019

Presentation TVT 2019

Meta-Analysis of 1-Year Outcomes of Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis

Presenter: Aaqib H Malik

June 13, 2019

Presentation TVT 2019

Low-Risk Approval: Who Isn’t a Candidate for TAVR?

Presenter: Tsuyoshi Kaneko

June 12, 2019

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Presenter: Martin B. Leon

June 16, 2016

Advertisement

Late-Breaking Clinical Science: Three-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

Key features for a first valve in a low-risk patient

TAVR and SAVR “Sequencing”: Lifelong Management Journey of Severe AS

Choosing the First TAVR Prosthesis: Self Expanding vs Balloon Expandable – Advantages and Disadvantages

Clinical and Anatomic Considerations for TAVR in a Young Patient (<65 yo): Durability, Coronary Access, and More

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Reactions From the Surgical Community

Reactions From the Cardiology Community

Highlights From the CoreValve Low-Risk Trial

Highlights From the PARTNER 3 Low-Risk Trial

The PARTNER 3 Low-Risk Randomized Trial

The Evolut Low-Risk Randomized Trial

Meta-Analysis of 1-Year Outcomes of Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis

Low-Risk Approval: Who Isn’t a Candidate for TAVR?

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content